📋 MOLECULIN BIOTECH, INC. (MBRX) - Clinical Trial Update
Filing Date: 2026-07-31
Accepted: 2026-07-31 08:00:12
Event Type: Clinical Trial Update
Event Details:
MOLECULIN BIOTECH, INC. (MBRX) Announces Clinical Trial Update
MOLECULIN BIOTECH, INC. (MBRX) provided an update on its clinical development programs.
Clinical Development Highlights:
Clinical Stage: Phase 2
Collaboration: MIRACLE
targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122
anticipated in the December 2026
expected in September 2026
🔬 Clinical Development Pipeline (MOLECULIN BIOTECH, INC.):
Product
Type
Development Stage
Therapeutic Area
Source
Liposomal Annamycin for Injection in combination with Cytarabine Injection.
Other
Phase PHASE2
Acute Myeloid Leukaemia (AML)
ClinicalTrials.gov
Radiation Therapy
Drug
Phase PHASE2
Glioblastoma, IDH-Wildtype
ClinicalTrials.gov
Placebo in combination with Cytarabine Injection
Other
Phase PHASE2
Acute Myeloid Leukaemia (AML)
ClinicalTrials.gov
WP1122
Other
Phase PHASE1
Healthy Volunteer
ClinicalTrials.gov
Surgical Procedure
Procedure
Phase PHASE2
Glioblastoma, IDH-Wildtype
ClinicalTrials.gov
STAT3 Inhibitor WP1066
Other
Phase PHASE2
Glioblastoma, IDH-Wildtype
ClinicalTrials.gov
Magnetic Resonance Imaging
Other
Phase PHASE2
Glioblastoma, IDH-Wildtype
ClinicalTrials.gov
Biospecimen Collection
Other
Phase PHASE2
Glioblastoma, IDH-Wildtype
ClinicalTrials.gov
Liposomal Annamycin Injection in combination with Cytarabine Injection
📋 MOLECULIN BIOTECH, INC. (MBRX) - Clinical Trial Update
Filing Date: 2026-07-31
Accepted: 2026-07-31 08:00:12
Event Type: Clinical Trial Update
Event Details:
🔬 Clinical Development Pipeline (MOLECULIN BIOTECH, INC.):
💼 Business Developments:
Structured Data: